Emerging Role of Gene Therapy in Cancer
DOI:
https://doi.org/10.61173/2r086b04Keywords:
Gene therapy, treatment strategy, targeted delivery, clinical researchAbstract
Cancer is one of the leading causes of death in the world, and researchers have been persistently studying the treatment of cancer. Although traditional treatment methods such as surgery, chemotherapy and radiotherapy are effective, they are often accompanied by serious side effects, drug resistance or limited effects on certain types of cancer. Therefore, it is urgent to develop more accurate and effective treatment plans. Cancer gene therapy is an innovative method to treat or prevent cancer by introducing or editing genetic material. Gene therapy brings new hope to the treatment of cancer, repairing mutant genes, activating the immune system or directly inducing cancer cell death. This review introduces some hot strategies of cancer gene therapy, including suicide gene therapy, tumor suppressor gene activation, immunotherapy, inhibition of oncogene activation, antiangiogenic gene therapy. The principles, application examples and advantages and disadvantages of these therapies in clinical research are also discussed. In addition, the challenges faced by gene therapy in improving safety and reducing side effects, and points out the direction of future research are also described, aiming to promote the transformation of these innovative therapies into conventional clinical applications.
References
[1] Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., & Manyazewal, T. (2021). New approaches and procedures for cancer treatment: Current perspectives. SAGE open medicine, 9, 20503121211034366.
[2] Navarro, S. A., Carrillo, E., Grinan-Lison, C., Martin, A., Peran, M., Marchal, J. A., & Boulaiz, H. (2016). Cancer suicide gene therapy: a patent review. Expert opinion on therapeutic patents, 26(9), 1095-1104.
[3] Li, Y., Zhao, S., Zhang, F., Jin, G., Zhou, Y., Li, P., & Yang, X. (2020). Molecular imaging-monitored radiofrequency hyperthermia-enhanced intratumoral herpes simplex virusthymidine kinase gene therapy for rat orthotopic ovarian cancer. International Journal of Hyperthermia, 37(1), 101-109.
[4] Du, W., & Searle, J. S. (2009). The rb pathway and cancer therapeutics. Current drug targets, 10(7), 581-589.
[5] Knudsen, E. S., Nambiar, R., Rosario, S. R., Smiraglia, D. Dean&Francis J., Goodrich, D. W., & Witkiewicz, A. K. (2020). Pan-cancer molecular analysis of the RB tumor suppressor pathway. Communications Biology, 3(1), 158.
[6] Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., & Cenciarelli, C. (2021). p53 signaling in cancer progression and therapy. Cancer cell international, 21(1), 703.
[7] Goel, S., Bergholz, J. S., & Zhao, J. J. (2022). Targeting CDK4 and CDK6 in cancer. Nature Reviews Cancer, 22(6), 356- 372.
[8] Ibnat, N., & Chowdhury, E. H. (2023). Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes. Scientific Reports, 13(1), 536.
[9] Huang, R., Li, X., He, Y., Zhu, W., Gao, L., Liu, Y., & Zhang, X. (2020). Recent advances in CAR-T cell engineering. Journal of hematology & oncology, 13, 1-19.
[10] Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature reviews Clinical oncology, 17(3), 147-167.
[11] Cappell, K. M., & Kochenderfer, J. N. (2023). Long-term outcomes following CAR T cell therapy: what we know so far. Nature reviews Clinical oncology, 20(6), 359-371.
[12] Braendstrup, P., Levine, B. L., & Ruella, M. (2020). The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy, 22(2), 57- 69.
[13] Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023). From bench to bedside: the history and progress of CAR T cell therapy. Frontiers in Immunology, 14, 1188049.
[14] Barresi, V., Musmeci, C., Rinaldi, A., & Condorelli, D. F. (2022). Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets. International Journal of Molecular Sciences, 23(16), 8875.
[15] Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021). Anti-angiogenic therapy: current challenges and future perspectives. International journal of molecular sciences, 22(7), 3765.
[16] Méndez-Valdés, G., Gómez-Hevia, F., Lillo-Moya, J., González-Fernández, T., Abelli, J., Cereceda-Cornejo, A., ... & Rodrigo, R. (2023). Endostatin and cancer therapy: a novel potential alternative to anti-VEGF monoclonal antibodies. Biomedicines, 11(3), 718.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
